![BioCentury This Week artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts123/v4/fb/22/95/fb22950f-4f1e-4c27-1678-e9d26780c410/mza_11443144383013806162.jpg/100x100bb.jpg)
Ep. 196 - CAR T's Next Act & Hudson's Vision for Sanofi
BioCentury This Week
English - October 03, 2023 00:00 - 29 minutes - 20.2 MB - ★★★★★ - 11 ratingsScience biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Biopharma companies are moving quickly to figure out how to optimize CAR T cell therapies for autoimmune diseases now that it’s becoming clear the modality has clinical activity and possibly even curative potential in the disease area. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the trigger for this surge of interest, the indications, targets and companies in play and whether the technology can meet the higher safety bar in autoimmune indications.
BioCentury’s editors also discuss takeaways from BioCentury’s recent conversation with Sanofi CEO Paul Hudson; the latest developments for the Inflation Reduction Act; and notable biotech financings, including a $300 million private placement for Structure Therapeutics.